Table 2.

List of publications and key trial characteristics, arranged by trial.

Trial ID	Phase	Masking	Multi-center	Age (years)	Diseasestage	Performancescore	Trialnumber	Principalpublication	Subsequentpublications
BRIM-8*	III	Double-blind	Yes	≥18	IIC–IIIC	ECOG 0-1	NCT01667419	Maio et al.14	Lewis et al.13
Caraceni 1998	—	—	—	18–70	IIIB	Karnofsky 100	—	Caraceni et al.24	—
CheckMate 238*	III	Double-blind	Yes	≥15	IIIB–IV	ECOG 0-1	NCT02388906	Weber et al.10	Weber et al.25
COMBI-AD	III	Double-blind	Yes	≥18	IIIA–IIIC	ECOG 0-1	NCT01682083	Long et al.26	Hauschild et al.27
EORTC 18071	III	Double-blind	Yes	≥18	IIIA–IIIC	ECOG 0-1	EUCTR2007-001974-10	Eggermont et al.9	Coens et al.28
							NCT00636168		Eggermont et al.29
									Eggermont et al.30
EORTC 18952	III	Open-label	Yes	18–70	IIB–IIIC	—	NCT00002763	Eggermont et al.31	Eggermont et al.32
							CDR0000064718
EORTC 18991	III	Open-label	Yes	18–70	III	ECOG 0-1	NCT00006249	Eggermont et al.33	Fusi et al.34
									Bottomley et al.35
									Eggermont et al.36
									Herndon et al.37
KEYNOTE 054	III	Double-blind	Yes	≥18	III	ECOG 0-1	NCT02362594	Eggermont et al.11	—
Lian 2013	II	—	No	≥18	II–III	ECOG 0-1	ChiCTR-TRC-11001798	Lian et al.38	—
Nordic IFN trial*	III	Open-label	Yes	≥18	IIB–III	ECOG 0-1	NCT01259934	Hansson et al.39	Vihinen et al.40
SWOG S0008	II	Open-label	Yes	≥10	IIIA–IIIC	Zubrod 0-1	NCT00006237	Flaherty et al.41	—
WHO MPT 16	II	Open-label	Yes	18–70	III	—	—	Cascinelli et al.42	—

Note: Trials are listed in alphabetical order; * denotes trials that provide stage III sub-group data.